Recombinant human erythropoietin in the treatment of nonrenal anemia
作者： Michael Heuser , Arnold Ganser
DOI: 10.1007/S00277-005-1086-5
关键词: Cancer 、 Radiation therapy 、 Hematology 、 Erythropoietin 、 Immunology 、 Internal medicine 、 Anemia 、 Oncology 、 Recombinant DNA 、 Chemotherapy 、 Medicine 、 Concomitant 、 General Medicine
摘要: Recombinant human erythropoietins (rhEPO) reliably increase hemoglobin levels in cancer patients experiencing chemotherapy-associated anemia. However, with “anemia of cancer” not being treated chemotherapy, rhEPO appears less effective. Recently, two studies have been broadly discussed which raised concern on the concomitant use erythropoietin and chemo- or radiation therapy patients. In addition, is generally considered cost-effective. Thus, application should be limited to indications proven clinical benefit. This review will provide an overview state art anemic discuss future developments.
springer.com
sci-hub.se 参考文章(103)
J L Spivak, Cancer-related anemia: its causes and characteristics. Seminars in Oncology. ,vol. 21, pp. 3- 8 ,(1994)
Vannucchi Am, Rossi-Ferrini P, Linari S, Saccardi R, Laszlo D, Bosi A, Lombardini L, Guidi S, Longo G, Ieri A, Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplantation. ,vol. 17, pp. 527- 531 ,(1996)
A. Spadea, G. Avvisati, E. Montefusco, M. C. Petti, M. A. Aloe Spiriti, R. Latagliata, V. Battistel, Erythropoietin treatment of idiopathic myelofibrosis. Haematologica. ,vol. 78, pp. 371- 373 ,(1993)
Kim Janatpour, Paul V. Holland, Noninfectious serious hazards of transfusion. Current hematology reports. ,vol. 1, pp. 149- 155 ,(2002)
Roger Waltzman, Denise Williams, Head-to-Head Comparison of Epoetin Alfa (EPO) 40,000 U QW vs Darbepoetin Alfa (DARB) 200 μg Q2W in Anemic Cancer Patients Receiving Chemotherapy (CT): Final Results of a Planned Interim Analysis (IA). Blood. ,vol. 104, pp. 4233- 4233 ,(2004) , 10.1182/BLOOD.V104.11.4233.4233
John Fetting, Paul Anderson, Harrison Ball, John Benear, Katy Benjamin, Charles Bennett, Susan Braun, Harmar Brereton, John Burrows, Charles Cobau, Alfred Cohen, Leslie Ford, Michael Friedman, Patricia Ganz, Richard Gelber, Holcombe Grier, Gerald Hanks, Robert Justice, Patricia Legant, Mark Levine, Susan Parsons, Peter Raich, Sandra Schafer, Thomas Smith, Collier Smyth, AT Van Oosterom, James Wade, Jane Weeks, Rodger Winn, Janet Woodcock, None, Outcomes of cancer treatment for technology assessment and cancer treatment guidelines Journal of Clinical Oncology. ,vol. 14, pp. 671- 679 ,(1996) , 10.1200/JCO.1996.14.2.671
K. Yonenobu, E. Wada, S. Suzuki, A. Kanazawa, The dorsal approach in degeneratively changed cervical spine Orthopade. ,vol. 25, pp. 533- ,(1996) , 10.1007/S001320050057
al-Khatti A, Stamatoyannopoulos G, Papayannopoulou T, Umemura T, Abels Ri, Vance J, Clow J, Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Transactions of the Association of American Physicians. ,vol. 101, pp. 54- 61 ,(1988)
John A Thompson, D Gary Gilliland, Josef T Prchal, John M Bennett, Kay Larholt, Richard A Nelson, Esther H Rose, Margaret H Dugan, GM/EPO MDS Study Group, None, Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome Blood. ,vol. 95, pp. 1175- 1179 ,(2000) , 10.1182/BLOOD.V95.4.1175.004K51_1175_1179
NJ Chao, JR Schriber, GD Long, RS Negrin, M Catolico, BW Brown, LL Miller, KG Blume, A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Blood. ,vol. 83, pp. 2823- 2828 ,(1994) , 10.1182/BLOOD.V83.10.2823.2823